{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:31:20Z","timestamp":1782883880025,"version":"3.54.5"},"publisher-location":"Chichester, UK","reference-count":131,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002003.pub3","type":"reference-entry","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T15:24:04Z","timestamp":1344439444000},"source":"Crossref","is-referenced-by-count":12,"title":["Beta-blockers for hypertension"],"prefix":"10.1002","author":[{"given":"Charles Shey","family":"Wiysonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel A","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Volmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani M","family":"Mayosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mbewu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel H","family":"Opie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,15]]},"reference":[{"key":"10.1002\/14651858.CD002003.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.ajkd.2011.07.018","article-title":"Comparison of Measured GFR, Serum Creatinine, Cystatin C, and Beta-Trace Protein to Predict ESRD in African Americans With Hypertensive CKD","volume":"58","author":"Bhavsar","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1002\/14651858.CD002003.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/HYPERTENSIONAHA.111.169367","article-title":"Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial","volume":"57","author":"Davis","year":"2011","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial","volume":"48","author":"Norris","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1002\/14651858.CD002003.pub3-BIB6|cit5","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub3-BIB5|cit6","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0197-2456(96)00081-5","article-title":"Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"17","author":"Wright","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD002003.pub3-BIB7|cit7","unstructured":"ASCOT Study Investigators Anglo Scandinavian Cardiac Outcomes Trial. ASCOT-BPLA preliminary results http:\/\/www.ascotstudy.org\/home.htm"},{"key":"10.1002\/14651858.CD002003.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk","volume":"29","author":"Gupta","year":"2011","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1464-5491.2011.03330.x","article-title":"Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach","volume":"28","author":"Gupta","year":"2011","journal-title":"Diabet Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Server","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002003.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"19","author":"Sever","year":"2001","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB14|cit13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(81)92624-6","article-title":"Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects","volume":"1","author":"Berglund","year":"1981","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB13|cit14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","article-title":"Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide","volume":"220","author":"Berglund","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1002\/14651858.CD002003.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"Br Med J"},{"key":"10.1002\/14651858.CD002003.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist Lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchett","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB18|cit17","first-page":"30","article-title":"Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)","volume":"4","author":"Zanchetti","year":"1996","journal-title":"Blood Press"},{"key":"10.1002\/14651858.CD002003.pub3-BIB17|cit18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00004872-199816070-00008","article-title":"Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis","volume":"16","author":"Zanchetti","year":"1998","journal-title":"J Hypertens"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub3-BIB20|cit19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0091-7435(81)90004-9","article-title":"Beta-blockers versus saluretics in hypertension. Comparison of total mortality, myocardial infarction, and sudden death: study design and early results on blood pressure reduction","volume":"10","author":"Wilhelmsen","year":"1981","journal-title":"Prev Med"},{"issue":"5","key":"10.1002\/14651858.CD002003.pub3-BIB19|cit20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J Hypertens"},{"issue":"5","key":"10.1002\/14651858.CD002003.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(98)00423-9","article-title":"Rationale and design of the International Verapamil SR\/Trandolapril (INVEST)","volume":"32","author":"Pepine","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"The IPPPSH Collaborative Group","volume":"3","year":"1985","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00549583","article-title":"The International Prospective Primary Prevention Study in Hypertension (IPPPSH): objectives and methods","volume":"27","year":"1984","journal-title":"Eur J Clin Pharmocol"},{"issue":"7 Pt 1","key":"10.1002\/14651858.CD002003.pub3-BIB26|cit26","first-page":"705","article-title":"The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group","volume":"10","author":"Dahlof","year":"1997","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1002\/14651858.CD002003.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension","volume":"32","author":"Dahlof","year":"1998","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindhom","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB30|cit30","first-page":"539","article-title":"Report of Medical Research Council Working Party on Mild to Moderate Hypertension","volume":"ii","year":"1981","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002003.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/hrt.59.3.364","article-title":"Medical Research Council Working Party on Mild Hypertension","volume":"59","year":"1988","journal-title":"Br Heart J"},{"issue":"No1 Pt 2","key":"10.1002\/14651858.CD002003.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0002-8703(88)90650-3","article-title":"The Medical Research Council Hypertension Trial: the smoking patient","volume":"115","author":"Dollery","year":"1988","journal-title":"Am Heart J"},{"issue":"suppl 3","key":"10.1002\/14651858.CD002003.pub3-BIB33|cit33","first-page":"S75","article-title":"An update on the Medical Research Council Trial","volume":"5","author":"Dollery","year":"1987","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results","volume":"291","year":"1985","journal-title":"Br Med J"},{"issue":"7","key":"10.1002\/14651858.CD002003.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1991.00400070161023","article-title":"A randomized, placebo- controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group","volume":"151","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"MRC Working Party","volume":"304","year":"1992","journal-title":"Br Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","year":"1998","journal-title":"Brit Med J"},{"key":"10.1002\/14651858.CD002003.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPRDS 38","volume":"317","year":"1998","journal-title":"Brit Med J"},{"key":"10.1002\/14651858.CD002003.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.1982.03330160044023","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial difference in response","volume":"248","year":"1982","journal-title":"JAMA"},{"issue":"16","key":"10.1002\/14651858.CD002003.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/jama.1982.03330160052024","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy","volume":"248","year":"1982","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of Intensive Blood-Pressure Controlin Type 2 Diabetes Mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-7-22","article-title":"First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation","volume":"7","author":"Zidek","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/hrt.2004.057703","article-title":"Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)","volume":"92","author":"Hjemdahl","year":"2006","journal-title":"Heart"},{"key":"10.1002\/14651858.CD002003.pub3-BIB45|cit45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD002003.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00004872-199011000-00002","article-title":"The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension","volume":"8","year":"1990","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clinthera.2008.01.007","article-title":"Comparison of the Effects of Doxazosin and Atenololon Target Organ Damage in Adults with Type 2 DiabetesMellitus and Hypertension in the CARDHIAC Study:A 9-Month, Prospective, Randomized, Open-Label,Blinded-Evaluation Trial","volume":"30","author":"VBarrios","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1474-4422(08)70263-1","article-title":"Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial","volume":"8","author":"Potter","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB50|cit50","first-page":"9-13","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"7-13","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in theCarvedilol or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub3-BIB53|cit52","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0197-2456(98)00013-0","article-title":"Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascualr Endpoints (CONVINCE) Trial","volume":"19","author":"Black","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD002003.pub3-BIB52|cit53","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1291\/hypres.28.331","article-title":"The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design.","volume":"28","author":"Ogihara","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1002\/14651858.CD002003.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the CarvedilolProspective Randomized Cumulative Survival (COPERNICUS)study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1751-7176.2010.00341.x","article-title":"Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study","volume":"12","author":"Bakris","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1002\/14651858.CD002003.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1470320308096411","article-title":"Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension","volume":"9","author":"Dietz","year":"2008","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1002\/14651858.CD002003.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/01.STR.24.4.543","article-title":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke","volume":"24","year":"1993","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD002003.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1559-4572.2008.00017.x","article-title":"Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.","volume":"3","author":"Phillips","year":"2008","journal-title":"J Cardiometab Syndr"},{"key":"10.1002\/14651858.CD002003.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischargeinitiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation ManagementPredischarge: Process for Assessment of Carvedilol Therapyin Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD002003.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ajh\/4.2.151","article-title":"Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study","volume":"4","author":"Olsson","year":"1991","journal-title":"Am J Hypertens"},{"issue":"6 Pt 2","key":"10.1002\/14651858.CD002003.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.13.6.773","article-title":"Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study","volume":"13","author":"Tuomilehto","year":"1989","journal-title":"Hypertension"},{"issue":"13","key":"10.1002\/14651858.CD002003.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/jama.1988.03720130040027","article-title":"Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study","volume":"259","author":"Wikstrand","year":"1988","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/01.HYP.17.4.579","article-title":"Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study","volume":"17","author":"Wikstrand","year":"1991","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cardfail.2011.05.001","article-title":"Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients","volume":"17","author":"Marazzi","year":"2011","journal-title":"J Card Fail"},{"key":"10.1002\/14651858.CD002003.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1182-1188","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of beta blocker initiation and titration in the MetoprololCR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT- HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/08038020701561745","article-title":"Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension","volume":"2","author":"Nilsson","year":"2007","journal-title":"Blood Press Suppl"},{"key":"10.1002\/14651858.CD002003.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of the effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002003.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/08037059309077174","article-title":"A prospective intervention trial of calcium antagonist therapy in hypertension","volume":"2","year":"1993","journal-title":"Blood Press"},{"key":"10.1002\/14651858.CD002003.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jacc.2008.09.046","article-title":"Blood Pressure Response UnderChronic Antihypertensive Drug TherapyThe Role of Aortic Stiffness in the REASON (Preterax inRegression of Arterial Stiffness in a Controlled Double-Blind) Study","volume":"53","author":"Protogerou","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB71|cit71","first-page":"378-384","article-title":"Effects of metoprolol CR inpatients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"215-25","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure(SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002003.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-198608000-00019","article-title":"STOP-Hypertension: Swedish Trial in Old Patients with Hypertension","volume":"4","author":"Dahlof","year":"1986","journal-title":"J Hypertens"},{"issue":"suppl 5","key":"10.1002\/14651858.CD002003.pub3-BIB74|cit74","first-page":"S607","article-title":"STOP-Hypertension - Preliminary Communication from the Pilot Study of the Swedish Trial in Old Patients with Hypertension","volume":"5","author":"Dahlof","year":"1987","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)","volume":"338","author":"Dahlof","year":"1991","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1002\/14651858.CD002003.pub3-BIB76|cit76","first-page":"S19","article-title":"Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study","volume":"11","author":"Ekbom","year":"1993","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/00004872-199210120-00013","article-title":"Antihypertensive efficacy and side-effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study","volume":"10","author":"Ekbom","year":"1992","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000107813","article-title":"Atenolol in the secondary prevention after stroke","volume":"5","author":"Eriksson","year":"1995","journal-title":"Cerebrovasc Dis"},{"key":"10.1002\/14651858.CD002003.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0895-7061(04)00863-5","article-title":"Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects","volume":"17","author":"Angeli","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB81|cit81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MJT.0b013e31817fd87e","article-title":"Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Balamuthusamy","year":"2009","journal-title":"Am J Ther"},{"key":"10.1002\/14651858.CD002003.pub3-BIB82|cit82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002003.pub3-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1062-72","DOI":"10.1016\/j.jacc.2008.05.057","article-title":"Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis","volume":"52","author":"Bangalore","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB85|cit85","article-title":"Combination of results from a series of 2 X 2 tables; control of confounding","volume-title":"Statistical methods in cancer research, Vol 1: The analysis of case-control data. IARC Scientific Publications","volume":"No. 32","author":"Breslow","year":"1980"},{"key":"10.1002\/14651858.CD002003.pub3-BIB86|cit86","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.CIR.102.6.677","article-title":"Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production","volume":"102","author":"Broeders","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/bmj.314.7089.1258","article-title":"Science, medicine and the future - Hypertension","volume":"314","author":"Brown","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD002003.pub3-BIB89|cit89","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003654.pub4","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Chen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub3-BIB90|cit90","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2","volume":"325","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/08037050701246386","article-title":"Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?","volume":"16","author":"Dahl\u00f6f","year":"2007","journal-title":"Blood Press"},{"key":"10.1002\/14651858.CD002003.pub3-BIB92|cit92","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(10)62036-3","article-title":"National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5\u00b74 million participants","volume":"377","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controll Clin Trials"},{"key":"10.1002\/14651858.CD002003.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pmed.0020133","article-title":"Rethinking the \"diseases of affluence\" paradigm: global patterns of nutritional risks in relation to economic development","volume":"2","author":"Ezzati","year":"2005","journal-title":"PLoS Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB95|cit95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/jhh.2010.11","article-title":"Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies","volume":"24","author":"Gradman","year":"2010","journal-title":"J Hum Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB96|cit96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002003.pub3-BIB97|cit97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB98|cit98","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume-title":"Available from www.cochrane-handbook.org","author":"Higgins","year":"2011"},{"issue":"24","key":"10.1002\/14651858.CD002003.pub3-BIB99|cit99","first-page":"2413","article-title":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","author":"JNC-6","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB100|cit100","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB101|cit101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11530710-000000000-00000","article-title":"Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release","volume":"70","author":"Kamp","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002003.pub3-BIB102|cit102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of [beta]-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB104|cit104","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should [beta] blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB105|cit105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0140-6736(96)07099-7","article-title":"Blood pressure control in the hypertensive population","volume":"349","author":"Mancia","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002003.pub3-BIB106|cit106","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1002\/14651858.CD002003.pub3-BIB107|cit107","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"N Eng J Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB108|cit108","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0895-7061(03)01017-3","article-title":"[beta]-blockers in hypertension--the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension","volume":"16","author":"Messerli","year":"2003","journal-title":"Am J of Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB109|cit109","volume-title":"Hypertension: management in adults in primary care: pharmacological update","year":"2006"},{"key":"10.1002\/14651858.CD002003.pub3-BIB110|cit110","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/bmj.315.7121.1544","article-title":"Evidence is needed that beta blockade alone reduces mortality in hypertension","volume":"315","author":"Opie","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB111|cit111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0735-1097(01)01728-4","article-title":"Evidence-based evaluation of calcium channel blockers for hypertension: Equality of mortality and cardiovascular risk relative to conventional therapy","volume":"39","author":"Opie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/14651858.CD002003.pub3-BIB112|cit112","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/01.hjh.0000133732.24501.9e","article-title":"Old antihypertensives and new diabetes","volume":"22","author":"Opie","year":"2004","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB113|cit113","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1370\/afm.708","article-title":"Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review","volume":"5","author":"Park","year":"2007","journal-title":"Ann Fam Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB114|cit114","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11906-007-0050-2","article-title":"The vasodilatory beta-blockers.","volume":"9","author":"Pedersen","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1002\/14651858.CD002003.pub3-BIB115|cit115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bmj.315.7101.154","article-title":"Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nifedipine and enalapril in antihypertensive treatment: results of the HANE study","volume":"315","author":"Philipp","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB116|cit116","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MBP.0b013e32833c8a64","article-title":"Different patterns of peripheral versus central blood pressure in hypertensive patients treated with \u03b2-blockers either with or without vasodilator properties or with angiotensin receptor blockers","volume":"15","author":"Pol\u00f3nia","year":"2010","journal-title":"Blood Press Monit"},{"key":"10.1002\/14651858.CD002003.pub3-BIB117|cit117","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002003.pub3-BIB118|cit118","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/bmj.319.7210.630","article-title":"British Hypertension Society Guidelines for Hypertension Management 1999; Summary","volume":"319","author":"Ramsay","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB119|cit119","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1751-7176.2011.00454.x","article-title":"Thiazide diuretics and \u03b2-blockers in the treatment of hypertension in diabetes mellitus","volume":"13","author":"Sander","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1002\/14651858.CD002003.pub3-BIB120|cit120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD002003.pub3-BIB121|cit121","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003","volume":"21","author":"Staessen","year":"2003","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB122|cit122","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB123|cit123","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","article-title":"Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention","volume":"46","author":"Verdecchia","year":"2005","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD002003.pub3-BIB124|cit124","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes:principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002003.pub3-BIB125|cit125","first-page":"351","article-title":"Beta-blockers and the treatment of hypertension: it is time to move on","volume":"18","author":"Wiysonge","year":"2007","journal-title":"Cardiovasc J Afr"},{"key":"10.1002\/14651858.CD002003.pub3-BIB126|cit126","first-page":"25","article-title":"Systematic review of anti-hypertensive therapies: Does the evidence assist in choosing a first-line drug?","volume":"161","author":"Wright","year":"1999","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD002003.pub3-BIB127|cit127","first-page":"188","article-title":"Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: Beta-blockers","volume":"163","author":"Wright","year":"2000","journal-title":"CMAJ"},{"issue":"3","key":"10.1002\/14651858.CD002003.pub3-BIB128|cit128","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008161","article-title":"First-line drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002003.pub3-BIB129|cit129","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.hjh.0000170370.41387.1b","article-title":"Evidence-based medicine in hypertension: what type of evidence?","volume":"23","author":"Zanchetti","year":"2005","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD002003.pub3-BIB130|cit130","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","article-title":"How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis","volume":"24","author":"Bradley","year":"2006","journal-title":"J Hypertens"},{"issue":"1","key":"10.1002\/14651858.CD002003.pub3-BIB131|cit131","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002003.pub2","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD002003.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:08:05Z","timestamp":1628543285000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002003.pub3"}},"subtitle":[],"editor":[{"given":"Charles Shey","family":"Wiysonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":131,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002003.pub3","relation":{},"subject":[],"published":{"date-parts":[[2012,8,15]]}}}